Wellington Management Group LLP Grows Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Wellington Management Group LLP lifted its position in Twist Bioscience Co. (NASDAQ:TWST) by 188.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 797,737 shares of the company’s stock after purchasing an additional 521,272 shares during the period. Wellington Management Group LLP owned about 1.36% of Twist Bioscience worth $36,042,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Signaturefd LLC raised its holdings in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after acquiring an additional 306 shares during the period. EdgeRock Capital LLC purchased a new position in Twist Bioscience in the 2nd quarter worth approximately $43,000. Blue Trust Inc. boosted its stake in Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after purchasing an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in Twist Bioscience during the 2nd quarter valued at approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after buying an additional 381 shares during the last quarter.

Analysts Set New Price Targets

TWST has been the subject of several research analyst reports. Evercore ISI raised their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Scotiabank raised their price objective on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 19th. Robert W. Baird boosted their target price on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 19th. Barclays cut their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Finally, TD Cowen reaffirmed a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $51.00.

Insider Buying and Selling

In related news, CFO Adam Laponis sold 856 shares of the business’s stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $41.81, for a total transaction of $35,789.36. Following the completion of the transaction, the chief financial officer now owns 73,397 shares in the company, valued at $3,068,728.57. The trade was a 1.15 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Paula Green sold 860 shares of the stock in a transaction on Friday, December 6th. The stock was sold at an average price of $52.70, for a total value of $45,322.00. Following the completion of the sale, the senior vice president now owns 133,715 shares in the company, valued at approximately $7,046,780.50. The trade was a 0.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 101,787 shares of company stock worth $4,584,508 over the last three months. 3.92% of the stock is owned by insiders.

Twist Bioscience Price Performance

NASDAQ:TWST opened at $47.39 on Friday. The firm has a market capitalization of $2.81 billion, a price-to-earnings ratio of -13.16 and a beta of 1.82. The business has a 50 day simple moving average of $44.85 and a 200-day simple moving average of $46.60. Twist Bioscience Co. has a 1 year low of $27.41 and a 1 year high of $60.90.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.